Posted inNews and Updates
FDA Grants Priority Review to Z-rostudirsen for Duchenne MD
The FDA has granted Priority Review to Dyne Therapeutics' z-rostudirsen. Learn how this novel therapy aims to treat Duchenne Muscular Dystrophy.
Posted inNews and Updates
FDA Approves Gene Therapy Trial for Tay-Sachs and Sandhoff
The FDA has authorized a new gene therapy trial for Tay-Sachs and Sandhoff diseases. Discover how this breakthrough could redefine treatment for rare disorders.
Posted inNews and Updates
Avatrombopag Study: New Data on Reducing Chemo Delays
New trial data shows oral avatrombopag effectively reduces chemotherapy delays by managing platelet counts, offering a breakthrough for cancer care.
Posted inNews and Updates
New Prediction Market Allows Betting on Drug Trial Results
New prediction markets now allow users to bet on the success of FDA drug trials. Explore the implications for biotech innovation and regulatory integrity.
Posted inNews and Updates
New Oral Drug Prevents Cancer Treatment Delays
A new oral drug successfully prevents chemotherapy-induced low platelet counts, helping cancer patients stay on their vital treatment schedules.
Posted inNews and Updates
Private University Initiates Dengue Vaccine Clinical Trials
A private university has launched clinical trials for a new dengue vaccine. Discover how this research could shape future immunization against the virus.
Posted inNews and Updates
Massive Bio & FOMAT Partner to Accelerate Cancer Trial Access
Massive Bio and FOMAT Medical Research partner to use AI-driven prescreening tools to help cancer patients find and enroll in critical clinical trials.
Posted inNews and Updates
Nuvation Bio Advances Glioma Drug to Phase III Trials
Nuvation Bio moves its glioma therapy to Phase III trials after positive three-year data shows improved patient survival and strong clinical efficacy.
Posted inNews and Updates
Samsung Biologics Eyes $1.8B Expansion into Peptide Market
Samsung Biologics plans a $1.8B acquisition of Swiss CDMO PolyPeptide, marking a strategic shift to expand its production capabilities into peptide medicines.
Posted inNews and Updates
CDSCO Approves Phase III Clinical Trial for Enlicitide
The CDSCO has authorized a Phase III trial for Enlicitide Decanoate. Learn about this critical step in the drug's clinical development and safety review.